Yau MS

ORCID: 0000-0002-0445-6334 · 1 paper in corpus

2023

Lowering of Circulating Sclerostin May Increase Risk of Atherosclerosis and Its Risk Factors: Evidence From a Genome-Wide Association Meta-Analysis Followed by Mendelian Randomization.

Arthritis & rheumatology (Hoboken, N.J.) ·doi:10.1002/art.42538

ObjectiveIn this study, we aimed to establish the causal effects of lowering sclerostin, target of the antiosteoporosis drug romosozumab, on atherosclerosis and its risk factors.MethodsA genome-wide association study meta-analysis was perfo…